<DOC>
	<DOCNO>NCT02139098</DOCNO>
	<brief_summary>The purpose study evaluate whether drug efficiency zolpidem amitriptyline condition accord learn theory patient primary insomnia .</brief_summary>
	<brief_title>Alternative Dosing Regimens Pharmacotherapy Insomnia</brief_title>
	<detailed_description>Previous research show repeated drug treatment regard conditioning process . Sleep disorder especially interest investigate perspective conditioning drug , since sleep quality define term subjective rating ( self-rated sleep quality parameter ) objective measure ( via polysomnographic assessment PSG ; e.g. , total sleep time , sleep onset , sleep architecture ) . By use two different drug ( zolpidem , amitriptyline ) modulate sleep differentially , investigator intend implement conditioning paradigm sleep disorder dissociate conditioning effect subjective objective sleep parameter . Both drug affect objective subjective sleep parameter positively , amitriptyline modulate objectively assess sleep architecture REM-suppression ( latency REM-sleep onset , percentage REM-sleep ) .Patients mild moderate insomnia undergo classical conditioning paradigm one two study medication : amitriptyline zolpidem . After acquisition period wash-out period , condition sleep change assess evocation trial . During second treatment phase 7 day , patient receive different dos amitriptyline ( 0mg 50mg per night ) zolpidem ( 0mg 5mg per night ) evaluate alternative dosing regimen pharmacotherapy mild moderate Insomnia .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<mesh_term>Zolpidem</mesh_term>
	<mesh_term>Amitriptyline , perphenazine drug combination</mesh_term>
	<criteria>1. age 18 year 69 year 2. fluent German language 3. provide write informed consent 4. ability understand explanation instruction give study physician investigator 1 . Sleep disorder cause medical factor ( e.g . sleep apnea , restless legs syndrome , narcolepsy , substanceinduced insomnia ) 2 . Contraindications study medication intake accord information sheet health professional ( Summary medicinal Product Characteristics , SmPC ; Fachinformation Germany ) assess physical examination ( include ECG ) medical history allergy amitriptyline hydrochloride ingredient allergy zolpidem ingredient acute intoxication alcohol , analgetics , hypnotic psychotropic drug urinary retention delirium untreated closedangle glaucoma prostatic hyperplasia pyloric stenosis paralytic ilius suicidal thought liver/ kidney/ pulmonary insufficiency myasthenia gravis hypokalemia bradycardia coronary heart disease , cardiac arrhythmia , long QT syndrome clinically relevant cardiac disorder increase risk seizures/ history seizure substance dependence syndrome/ history substance dependence syndrome 3 . Allergies ingredient placebo noveltasting drink ( CS ) 4. currently pregnant ( verified urine pregnancy test ) lactate 5. patient score â‰¥12 Epworth Sleepiness Scale 6. patient score 8 21 Insomnia Severity Index 7. patient suffer mental disorder verify SCID ( major depression ; psychosis ; brain injury ; substance abuse dependency syndrome last 6 month V1 ) 8. nicotine consumption &gt; 10 cigarettes/day 9. unwillingness refrain alcohol consumption throughout study 10 . Concomitant medication interfere study medication intake due potential interaction ( psychotropic medication include analgetics muscle relaxant , hypericum derivative ; antihypertensive ; antiarrhythmic agent ; antibiotic ; cisaprid ; antimalaria drug ; diuretic ; imidazole antifungal ; cumarin derivative ; antihistaminics ; calcium channel blocker ; medication enlarge QT interval may lead hypokalemia ) 11. change concomitant medication regime last 2 week prior visit 1 randomization 12. intake psychotropic medication last 3 month 13. participation clinical trial 3 month prior visit 1 14. woman childbearing age use 2 highly effective contraceptive method 15. employee Sponsor principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>sleep architecture</keyword>
	<keyword>condition pharmacological response</keyword>
	<keyword>insomnia</keyword>
</DOC>